Investor Relations

About Us

PAVmed is a medical device company employing a business model to bring innovative products from concept to commercialization with speed and capital efficiency, while enhancing and accelerating value creation.

PAVmed is building a deep pipeline of products encompassing a broad spectrum of clinical areas possessing attractive regulatory pathways and market opportunities currently exceeding $4 billion.  The company currently has five lead products to provide multiple near-term value creation opportunities

The Company is led by a team of accomplished medical device entrepreneurs. The leadership team has previously successfully implemented its unique business model of creating value with modest capital investment in four single-product companies, each of which rapidly advanced towards commercialization. Two of these four products have been cleared and commercialized, while two products are currently undergoing FDA review. PAVmed leverages this unique business model.

By establishing a long-term multi-product company with access to public capital, the company plans to build an expanding pipeline of innovative products across a range of specialties and clinical conditions.

Recent Press Releases

  • 1/19/18 8:25 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced the pricing of its previously announced underwritten public offering of 2,415,278 shares of its common stock at a price to the public of $1.80 per share. In addition, PAVmed has granted the underwriters of the offering a 45-day option to purchase up to 362,292 additional shares of its common stock to cover overallotments,more...
  • 1/18/18 5:56 pm EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW)) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it intends to offer shares of common stock in an underwritten public offering. PAVmed also expects to grant to the underwriters a 45-day option to purchase additional shares of common stock to cover overallotments, if any. PAVmed intends to use the net proceeds from this offering for working capital and other generalmore...
  • 1/17/18 7:30 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company has set the terms of its previously announced rights offering (the “Rights Offering”). Pursuant to the Rights Offering, the Company will distribute to the holders of outstanding shares of its Common Stock (Nasdaq: PAVM), for no consideration, one transferable right (the “Right”) to purchase amore...

In the News

  • Forbes
    11/7/16 5:13 pm EST

    Shares of small-capitalization companies have been busy beavers, besting larger-cap stocks since February after a long period of under-performance, with the Russell 2000 outscoring the S&P 500-stock index. And analysts point out that small-cap investing has proven to be the better play for the long term.

SEC Filings

Click Here to view PAVmed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation

PROXY MATERIALS

Click Here to view the Proxy Statement for PAVmed Inc 2017 Annual Meeting

Click Here to view the Annual Report for PAVmed Inc 2017 Annual Meeting